malignancies: influence of antibody isotype Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid

Summary 0 f Patients Treated With CAMPATH-1 AntibodiesBlOOd Malignant . PauentD fays 0 SteroidLymphocytes Ix 109/L) Marrow Infiltration (%) Spleen (cm Palpable) . Lymph Nodes and Other SitesNo. Age/Sex Disease Treatment Before After Before After Before After of DiseaseTreated with gM CAMPATH-1 M2161/M NHL grade II 0 10 10 83 ND 6 6 Axillary, inguinal, hepaticinfiltration73/M B-CLL 0 42 25 ND ND 5 5 Hepatic infiltrationTreated with IgG2b CAMPATH- 1G1 67/M PLL 2 85 0 95 0 6 0 CNS2 67/F PLL 2 60 0 97 87 - - - 3 55/M BCLL 2 5 0 99 89 6 0 - 4 54/M HCL 0 60 0 ND ND (Splenectomized) - 5 55/F Ph Null ALL 1 35 0 97 21 - - - 6 24/M cALL 0 0 0 2 0 - - - 7 6/M cALL 0 7 0 99 79 4 0 - 8 56/M B-ALL 2 2.5 0 60 0 - - CNS9 37/M B-ALL 2 0.3 0 90 0 - - CNS, hepatic infiltrates10 73/F NHL11 1 68/M NHL [grade I12 67/M NHL stape IVB13 76/F NHLJ14 56/F NHL11 5 24/F NHL 01000028 032 0220 00.8 00 00 078 090 7695 ND15 20 ND0 ND18 810 2 - - 23 14 - -- -- AbdominalThoracic, abdominal - CervicalInguinal, abdominal16 33/F NHL grade II 0 0 0 0 ND